The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice versa.

Distinct patterns of symptom severity among patients with COPD sheds light on the heterogeneous nature of the patients’ ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...

A study by doctoral student Adriana Eugene and Distinguished Professor Luisa N. Borrell found that older adults who use ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.